---
title: "REG - AIM - AIM Notice - 26/02/2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277002244.md"
description: "The London Stock Exchange has admitted the following securities to trading on AIM as of February 26, 2026: Allergy Therapeutics Plc with 191,089,599 ordinary shares, hVIVO plc with 1,386,991 ordinary shares, and UNITED OIL & GAS PLC with 330,000,000 ordinary shares under block admission. For further inquiries, contact Market Operations."
datetime: "2026-02-26T08:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277002244.md)
  - [en](https://longbridge.com/en/news/277002244.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277002244.md)
---

# REG - AIM - AIM Notice - 26/02/2026

RNS Number : 3908U AIM 26 February 2026

NOTICE

26/02/2026 - 08:00

The London Stock Exchange admits the following securities to trading on AIM:

Allergy Therapeutics Plc

191,089,599

ORDINARY SHARES OF 0.1P EACH, FULLY PAID

(B02LCQ0)(GB00B02LCQ05)

hVIVO plc

1,386,991

ORDINARY SHARES OF 0.1P EACH FULLY PAID

(B9275X9)(GB00B9275X97)

UNITED OIL & GAS PLC

330,000,000

Block Admission

ORDINARY SHARES OF GBP0.00001 EACH; FULLY PAID

(BYX0MB9)(GB00BYX0MB92)

If you have any queries or require further information, please contact Market Operations on 020 7797 4310.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END AMOBBGDDCBDDGLU

### Related Stocks

- [ITRM.US](https://longbridge.com/en/quote/ITRM.US.md)
- [ALLR.US](https://longbridge.com/en/quote/ALLR.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [NBRVF.US](https://longbridge.com/en/quote/NBRVF.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ITRMF.US](https://longbridge.com/en/quote/ITRMF.US.md)

## Related News & Research

- [Allarity Therapeutics Q1 net loss per share narrows](https://longbridge.com/en/news/286612460.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)